<p>Cancer Care Management During the COVID-19 Pandemic</p>

Abstract

New cases of the novel coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are increasing around the world. Currently, health care services are mainly focused on responding to and controlling the unique challenges of the coronavirus disease 2019 (COVID-19) pandemic. These changes, along with the higher susceptibility of patients with cancer to infections, have profound effects on other critical aspects of care and pose a serious challenge for the treatment of such patients. During the COVID-19 pandemic, it is important to provide strategies for managing the treatment of patients with cancer to limit COVID-19-associated risks at this difficult time. The present study set out to summarize the latest research on epidemiology, pathogenesis, and clinical features of COVID-19. We also address some of the current challenges associated with the management of patients with cancer during the COVID-19 pandemic and provide practical guidance to clinically deal with these challenges.

Post‐traumatic stress symptomatology and adjustment of medical oncology practice during the COVID‐19 pandemic among adult patients with cancer in a day care hospital

“…30 A 5-point Likert scale is used to rate each item from 0 (no problem) to 4 (very severe problem). The total score ranges from 0 to 28 and is interpreted as follows: absence of insomnia (0-7), subthreshold insomnia (8)(9)(10)(11)(12)(13)(14), moderate insomnia (15)(16)(17)(18)(19)(20)(21), and severe insomnia (22)(23)(24)(25)(26)(27)(28).…”

“…4 In response to both this higher vulnerability of patients with cancer to COVID-19 and the lockdown measures, guidelines were issued to adjust oncologic care during the COVID-19 pandemic. [5][6][7][8][9][10][11][12][13][14] This led to frequent delays and disruptions in cancer health care. 15 Altogether, the fear of becoming infected, 16,17 the fear of cancer care disruption, and social isolation because of the lockdown measures 18 may have added stress in an already vulnerable cancer population.…”

Rational approaches to discover SARS-CoV-2/ACE2 interaction inhibitors: from pharmacophore-based virtual screening to molecular dynamics

“…Cluster 1 (Asp30, Lys31, And His34) with a score of 0.863 covers the only region (2) of the complex. Clusters 2 (Thr27; Lys31; His34), cluster 3 (Thr27; Asp30; His34), and cluster 5 (Gln24; Thr27; Asp30) with scores of 0.821, 0.804, and 0.780, respectively, cover regions (2) and (3). Also, regions (1) and (2) were covered by clusters 4 (Lys31; His34; Asp38) and 6 (His34; Asp38; Lys353) with a score of 0.78 and 0.58.…”

“…In the last two decades, two outbreaks have also been caused by coronaviruses, severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), occurring in 2002 and 2012, respectively [1]. The recent outbreak, severe acute respiratory syndrome (SARS-CoV-2), was first identified in China and spread so rapidly around the world that the World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020 [2]. The prevalence of COVID-19 and the mortality rate from respiratory disease and multiple organ damage have not yet been controlled.…”

The risk of pancreatic adenocarcinoma following SARS-CoV family infection

“…Patients with mild symptoms are reported to recover after one week, while in severe cases, due to virus-induced alveolar damage, they experience progressive respiratory failure which may lead to death 2 . In March 2020, the World Health Organization (WHO) identified Covid-19 as a pandemic and called on governments around the world to manage the protection of the population against COVID-19 3 , 4 . Considering the wide range of infections with this virus and given that lack of information regarding the pathogenesis and even transmission, there have been concerns about the consequences following infection with SARS-CoV-2 virus.…”